^
Association details:
Biomarker:KRAS G12C
Cancer:Lung Cancer
Drug:icovamenib (BMF-219) (Menin-MLL inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

Irreversible menin inhibitor, BMF-219, inhibits the growth of KRAS-mutated solid tumors Add to My Itinerary

Published date:
03/09/2022
Excerpt:
BMF-219 inhibited cell viability ≥ 90% in six of eight KRAS G12C lung cancer lines….Complete abrogation of growth was observed in all samples with IC50 values ranging between 0.2 μM - 0.6 μM....High potency of BMF-219 was observed amongst various KRAS-mutant cell lines suggesting that BMF-219 broadly inhibits these tumors.